Last reviewed · How we verify
Minoxidil Tablets
Minoxidil is a potassium channel opener that vasodilates blood vessels and may stimulate hair follicle growth through increased blood flow and prolongation of the anagen (growth) phase.
Minoxidil is a potassium channel opener that vasodilates blood vessels and may stimulate hair follicle growth through increased blood flow and prolongation of the anagen (growth) phase. Used for Androgenetic alopecia (male and female pattern hair loss), Alopecia areata.
At a glance
| Generic name | Minoxidil Tablets |
|---|---|
| Sponsor | Industrial Farmacéutica Cantabria, S.A. |
| Drug class | Potassium channel opener; topical/systemic antialopecia agent |
| Target | ATP-sensitive potassium channels (KATP); hair follicle growth pathways |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Minoxidil opens ATP-sensitive potassium channels in vascular smooth muscle, causing vasodilation and increased blood flow to hair follicles. It also directly stimulates hair follicle growth and extends the anagen phase of the hair growth cycle. The exact mechanism of action on hair follicles remains incompletely understood but involves both vascular and direct follicular effects.
Approved indications
- Androgenetic alopecia (male and female pattern hair loss)
- Alopecia areata
Common side effects
- Hypertrichosis (excessive hair growth)
- Dermatitis/contact dermatitis
- Pruritus
- Erythema
- Headache (systemic formulation)
- Tachycardia (systemic formulation)
- Fluid retention (systemic formulation)
Key clinical trials
- Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia (PHASE3)
- Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia (PHASE3)
- Efficacy & Safety of Minoxidil SL Tablets in Men With AGA (PHASE3)
- Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia (EARLY_PHASE1)
- Phase 1 Pharmacokinetic Study of Minoxidil SL Tablets (PHASE1)
- Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss (PHASE3)
- Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia (PHASE3)
- Bioavailability Clinical Trial of Oral Minoxidil 1 mg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minoxidil Tablets CI brief — competitive landscape report
- Minoxidil Tablets updates RSS · CI watch RSS
- Industrial Farmacéutica Cantabria, S.A. portfolio CI